Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes : a post hoc analysis of the SABINA III study
| dc.contributor.author | Price, David | |
| dc.contributor.author | Beekman, Maarten j. h. i. | |
| dc.contributor.author | Mattarucco, Walter javier | |
| dc.contributor.author | Barriga-Acevedo, Rocio martina | |
| dc.contributor.author | Wang, Hao-Chien | |
| dc.contributor.author | Diaz, Dina v. | |
| dc.contributor.author | Khattab, Adel | |
| dc.contributor.author | Pacheco gallego, Manuel | |
| dc.contributor.author | Al zaabi, Ashraf | |
| dc.contributor.author | Farouk, Hisham | |
| dc.contributor.author | Attar-Zadeh, Darush | |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.date.accessioned | 2024-11-04T14:21:01Z | |
| dc.date.available | 2024-11-04T14:21:01Z | |
| dc.date.issued | 2024-11-01 | |
| dc.description | Acknowledgements AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study, and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided by Praveen Kaul, PhD, of Cactus Life Sciences (part of Cactus Communications), Mumbai, India, in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460) and fully funded by AstraZeneca. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 10 | |
| dc.format.extent | 1627990 | |
| dc.identifier | 298380750 | |
| dc.identifier | 2ffa01ed-e473-450a-9b7d-46d61054edcd | |
| dc.identifier | 85208290306 | |
| dc.identifier.citation | Price, D, Beekman, M J H I, Mattarucco, W J, Barriga-Acevedo, R M, Wang, H-C, Diaz, D V, Khattab, A, Pacheco gallego, M, Al zaabi, A, Farouk, H & Attar-Zadeh, D 2024, 'Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes : a post hoc analysis of the SABINA III study', npj Primary Care Respiratory Medicine, vol. 34, no. 1, 34. https://doi.org/10.1038/s41533-024-00397-4 | en |
| dc.identifier.doi | 10.1038/s41533-024-00397-4 | |
| dc.identifier.iss | 1 | en |
| dc.identifier.issn | 2055-1010 | |
| dc.identifier.other | crossref: 10.1038/s41533-024-00397-4 | |
| dc.identifier.uri | https://hdl.handle.net/2164/24539 | |
| dc.identifier.vol | 34 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | npj Primary Care Respiratory Medicine | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | asthma | en |
| dc.subject | health policy | en |
| dc.subject | R Medicine | en |
| dc.subject | Supplementary Information | en |
| dc.subject.lcc | R | en |
| dc.title | Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes : a post hoc analysis of the SABINA III study | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Price_etal_NPJPCRM_Over_The_Counter_VoR.pdf
- Size:
- 1.55 MB
- Format:
- Adobe Portable Document Format
